Monitoring the Heart
The following is from the current issue (Spring 2007) of the CURE magazine:
Monitoring the Heart
Patients receiving potentially cardiotoxic cancer therapy should be carefully monitored both during and after treatment. An echocardiogram (heart ultrasound) is the primary tool used to monitor heart health, but other tests may also be done, including blood tests, electrocardiograms or multiple-gated acquisition (MUGA) scans, which produce a moving image of the heart muscle.
M.D. Anderson Cancer Center's department of cardiology recently sponsored a panel discussion of oncologists and cardiologists to discuss how to best monitor a patient's heart function. Concerning the issue of whether to use non-invasive echocardiogram or time-consuming yet genearally more precise MUGA, the panel determined either imaging method was acceptable depending on the expertise of the radiologists and cardiologists at a particular cancer center.
Following treatment, survivors should have a yearly checkup to identify any long-term consequences of cancer therapy. Those at higher risk for heart complications may need more frequent monitoring.
__________________
Blessings and Peace,
Barbara
DX Oct 02 @ age 52 Stage 2B Grade 3 Mastectomy
"at least" 4.5 cm IDC 1+node ER+61% /PR-
Assiciated Intraductual component with Comedo Necrosis
Her2+ FISH8.6 IHC 2+
5 1/2 CEF Arimidex
Celebrex 400mg daily for 13 months
Prophylactic mastectomy
Estradiol #: 13
PTEN positive, "late" Herceptin (26 months after chemo)
Oct 05: Actonel for osteopenia from Arimidex.
May 08: Replaced Actonel with Zometa . Taking every 6
months.
Accepting the gift of life, I give thanks for it and live it in fullness.
|